nVerses Capital’s Sage Therapeutics SAGE Stock Holding History

nVerses Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400	Closed	-$7.5K	–	1182
2024 Q1	$7.5K	Buy	+400	New	+$9.23K	0.02%	525

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

nVerses Capital's SAGE Position: Q2 2024 in Review

nVerses Capital sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 400 shares — an estimated $7.5K sold.

nVerses Capital first reported a position in SAGE in Q1 2024 and held it in 1 quarter. The position peaked at $7.5K in Q1 2024. 193 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

nVerses Capital reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
nVerses Capital sold 400 Sage Therapeutics shares in Q2 2024, an estimated $7.5K.
nVerses Capital first reported a position in Sage Therapeutics in Q1 2024 and held it in 1 quarter.
nVerses Capital's Sage Therapeutics position peaked at $7.5K in Q1 2024.
193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.